About CEO Pierluigi Antonelli

CEO Fresenius Kabi Pierluigi Antonelli

Pierluigi Antonelli, 56, became Chairman of the Management Board of Fresenius Kabi (equivalent to President and CEO) on March 1, 2023. He joined Fresenius with extensive operational expertise in the pharmaceutical industry with a focus on product development and launches across key international markets, business development and strategy crafting as well as implementation.

In his previous role since 2019, he was the CEO of Angelini Pharma, a company of the Italian Angelini Group specializing in brain health and consumer health. Prior to that, he held senior leadership positions at Novartis Oncology, Sandoz, Merck & Co. and Bristol Myers Squibb in the United States as well as across Europe.